A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in Relapsed or Refractory Acute Myeloid Leukemia

There is no standard salvage chemotherapy regimen for relapsed or refractory (RR) Acute Myeloid Leukemia (AML). Preclinical data suggested synergy in vitro between cytarabine and Imatinib Mesylate (IM) on AML cell growth inhibition. After demonstrating safety and feasibility with a phase I study, we conducted a phase 2 clinical study of Cladribine, Cytarabine, G-CSF (CLAG) regimen in combination with IM in patients with RR-AML.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List, Rami S. Komrokji Source Type: research